Showing results (21-30 of 26) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Bioorganic & Medicinal Chemistry Letters|September 30, 2011
Investigation of the pyrazinones as PDE5 inhibitors: evaluation of regioisomeric projections into the solvent regionRobert O Hughes, Todd Maddux, D Joseph Rogier, et al.The AAPS Journal|July 29, 2021
An Integrated Analysis of Dostarlimab ImmunogenicitySharon Lu, Ronald R Bowsher, Amanda Clancy, et al.Mabs|July 27, 2021
Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal modelsSujatha Kumar, Srimoyee Ghosh, Geeta Sharma, et al.Journal for Immunotherapy of Cancer|March 25, 2022
IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin-paclitaxel, with or without bevacizumab in patients with advanced cancerTimothy A Yap, Alberto Bessudo, Erika Hamilton, et al.Cancer|September 3, 2021
JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancerSuresh S Ramalingam, Eddie Thara, Mark M Awad, et al.British Journal of Cancer|June 21, 2019
A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomasChia-Chi Lin, Hendrik-Tobias Arkenau, Sharon Lu, et al.Pageof 3